



Study Director/Sponsor: Bristol-Myers Squibb Company ClinicalTrials.gov Identifier: NCT01642004



A Phase III trial of the anti-PD-1 monoclonal antibody BMS-936558 versus docetaxel in previously treated advanced or metastatic squamous cell NSCLC • Estimated primary completion: August 2014 (Target N = 264) • Eligibility: Stage IIIB/IV or recurrent squamous cell NSCLC; recurred or progressed on or after 1 prior platinum-containing chemotherapy regimen







DR BRAHMER

The Phase I data with the anti-PD-1 monoclonal antibody are exciting in that this is the first

time we've observed robust responses to antibody therapy in patients with lung cancer. For 76 patients, the reported response rate was 18%. The response rate among patients with squamous cell histology was approximately 33% and for patients with nonsquamous cell histology it was approximately 11%. But it is important to realize that most of these patients' disease was heavily pretreated. So the fact that we saw long-lasting responses is interesting. The progression-free survival rate for the patients who were followed for 6 months was higher than 20%. The responses are maintained with time and, in my experience, are longer than those in patients who receive chemotherapy, particularly among those with heavily pretreated disease. A handful of patients are beyond 2 years without needing therapy.



DR GOVINDAN

This is a high-priority trial, and I've heard a lot of interest and enthusiasm in evaluating immunotherapy in patients with metastatic squamous cell NSCLC. This is a great compound and a great study for these patients.

